Acceleration 2012: Nutter Early Stage Life Sciences Conference
Tuesday, November 13 2012
3:00 pm – 6:30 pm
Location: Nutter McClennen & Fish LLP, Louis D. Brandeis Conference Center, 155 Seaport Boulevard, Boston, MA 02210
Where Biotech, Pharma and Medical Device executives and entrepreneurs explore how investment and innovation lead to business acceleration. An outstanding line-up of speakers is coming together for this conference to examine current issues and trends in early-stage development among life science companies. Join us to hear compelling experiences, perspectives and insights from industry leaders and innovators.
ACCELERATION 2012: Nutter Early Stage Life Sciences Conference
DIRECTIONS & PARKING
Robert S. Langer, Sc.D.
David H. Koch Institute Professor, Massachusetts Institute of Technology
Who benefits from attending:
- Entrepreneurs in medical device, pharma and biotech companies
- Angel, Venture Capital and Private Equity life science investors
- C-level executives and business development professionals from large medical device, pharma and biotech companies
TRENDS IN EARLY-STAGE FINANCE AND DEAL STRUCTURES
Chief Executive Officer
Halloran Consulting Group
Omar Amirana, M.D.
Third Rock Ventures
Managing Director, Praxis Advisors
Susan Windham-Bannister, Ph.D.
President & CEO
Massachusetts Life Sciences Center
The amount of venture capital invested in the life sciences sector during the second quarter of 2012 decreased for the fourth consecutive quarter, shrinking by 39% compared to the same period in 2011. In spite of the adverse funding environment, and perhaps because of it, experimentation with innovative early-stage funding models and deal structures is taking place among development-stage life science companies, venture capital funds, and large pharmaceutical and medical device firms.
Our panel of life science venture capitalists and angel investors will explore recent funding collaborations between venture capital and large life science companies, innovative way to attract investment and generate shareholder returns, the role of non-dilutive capital, and other mechanisms to preserve value for founders and early investors of emerging life sciences companies.
BUILDING BLOCKS OF SUCCESSFUL BUSINESS DEVELOPMENT:
MAXIMIZING VALUE CREATION AND ATTRACTING BUYERS
Michelle L. Basil
Co-Chair, Life Science Group
Nutter McClennen & Fish
David H. Donabedian, Ph.D.
Senior Vice President
Locust Walk Partners
SV Life Sciences
Leslie J. Williams, BS, RN, MBA
Chief Executive Officer
Leading a successful life sciences company requires the formulation and execution of a multi-dimensional business development plan. This panel will discuss the key building-blocks for a successful business development strategy that positions a life science company for an attractive exit opportunity. Topics examined will include the importance of clinical strategy, planning for regulatory and reimbursement challenges, negotiating strategic collaborations, and how and when to engage with potential acquirers or partners.